UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP)…
COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc…
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in…
CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)…
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327…
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected…
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed…